Figure 2.

ACE2 receptor blocking antibodies in patients with varying severity of illness and following a single dose of the AZD1222 vaccine. ACE receptor blocking antibodies were measured by the surrogate virus neutralizing test following natural infection at 4 weeks in those with mild illness (n = 15) and moderate/severe illness (n = 15) and at 12 weeks in those with mild (n = 14) and moderate/severe illness (n = 6). Antibodies were also measured at 4 weeks (n = 20) and 12 weeks (n = 20) in vaccines following a single dose of AZD1222. The Kurskal–Wallis test was used to determine the difference between the antibody levels between the three different groups (two-tailed) followed by multiple comparisons using two-stage step-up procedure of Benjamini, Krieger, and Yekutieli while controlling the false discovery rate (FDR). The lines indicate the median and the interquartile range.